NovoCure Ltd

038

Company Profile

  • Business description

    NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

  • Contact

    Grenville Street
    No. 4 The Forum, Second Floor
    St. HelierJE2 4UF
    JEY

    T: +44 1534756700

    E: [email protected]

    https://www.novocure.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2026

    Employees

    1,605

Stocks News & Analysis

stocks

Nvidia: Hugging Face acquisition both a wise offensive and defensive move

We think this improves Nvidia’s position within the open-source community.
stocks

Anthropic’s IPO will be huge—and risky. Here are the challenges investors should watch

Part two of a Q&A with PitchBook senior analyst Harrison Rolfes about Anthropic, the AI giant’s challenges, and how much it’s worth.
stocks

Chart of the Week: China demand for copper falls amidst record rally

Elevated copper prices raise valuation questions.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,196.0054.60-0.59%
CAC 408,278.777.63-0.09%
DAX 4026,046.4043.080.17%
Dow JONES (US)53,426.31259.80-0.48%
FTSE 10010,831.090.43-0.00%
HKSE25,650.87437.561.74%
NASDAQ26,493.0691.00-0.34%
Nikkei 22565,020.94806.461.26%
NZX 50 Index13,974.18128.000.92%
S&P 5007,717.2830.43-0.39%
S&P/ASX 2009,005.9064.30-0.71%
SSE Composite Index3,930.1211.97-0.30%

Market Movers